Sign up for the QMED & MD+DI Daily newsletter.
Study Could Boost Stent SalesStudy Could Boost Stent Sales
A study published in the New England Journal of Medicine suggests that drug-eluting stents might be more effective than their bare-metal counterparts. As part of the study, 7.4% of patients that had the DES needed another procedure within two years to restore blood flow versus the 10.7% rate for those who had a bare-metal stent implanted.
October 4, 2007
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
And after three years, 5.5% of the patients with the DES had died compared to 7.8% of patients with the bare-metal stents.In other stent news, Medtronic is expecting FDA to approve its Endeavor stent by the end of this year. According to analysts, the device has a safety profile that puts it above J&J and Boston Scientific.
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
_(2).png?width=300&auto=webp&quality=80&disable=upscale)